{"id":"NCT00550953","sponsor":"Boehringer Ingelheim","briefTitle":"Filtered Trial for Telmisartan 40mg Non-responder","officialTitle":"Filtered Trial for Telmisartan 40mg Non-responder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-07","completion":null,"firstPosted":"2007-10-30","resultsPosted":"2010-02-02","lastUpdate":"2014-01-30"},"enrollment":314,"design":{"allocation":null,"model":"PARALLEL","masking":null,"primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"telmisartan+amlodipine","otherNames":[]},{"type":"DRUG","name":"telmisartan","otherNames":[]}],"arms":[],"summary":"The primary purpose of this study is to:\n\nDemonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy.","primaryOutcome":{"measure":"Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks","timeFrame":"Baseline and 8 Weeks","effectByArm":[{"arm":"Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination","deltaMin":13.49,"sd":0.63},{"arm":"Telmisartan 40 mg Monotherapy","deltaMin":5.47,"sd":0.62}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":156},"commonTop":["Nasopharyngitis"]}}